Adalimumab for Treating Moderate-to-Severe Hidradenitis Suppurativa: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

[1]  J. Higgins,et al.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, International Coaching Psychology Review.

[2]  J. Ingram,et al.  Management of hidradenitis suppurativa: a U.K. survey of current practice , 2015, The British journal of dermatology.

[3]  J. Lapins,et al.  European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[4]  A. Kimball,et al.  Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment , 2014, The British journal of dermatology.

[5]  J. Ingram.  Hidradenitis suppurativa outcome measures and treatment goals , 2014, The British journal of dermatology.

[6]  G. Jemec,et al.  Hidradenitis suppurativa: a common and burdensome, yet under-recognised, inflammatory skin disease , 2014, Postgraduate Medical Journal.

[7]  M. Jonkman,et al.  Systemic therapy with immunosuppressive agents and retinoids in hidradenitis suppurativa: a systematic review , 2013, The British journal of dermatology.

[8]  G. Jemec.  Clinical practice. Hidradenitis suppurativa. , 2012, The New England journal of medicine.

[9]  J. Revuz.  Hidradenitis suppurativa , 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.

[10]  G. Jemec,et al.  Morbidity in patients with hidradenitis suppurativa , 2001, The British journal of dermatology.

[11]  H. Williams,et al.  The natural history of hidradenitis suppurativa , 2000, Journal of the European Academy of Dermatology and Venereology : JEADV.

[12]  M. Cowie.  National Institute for Health and Care Excellence. , 2015, European heart journal.

[13]  Disciplinary Committee,et al.  Royal Pharmaceutical Society of Great Britain , 2002 .